The start-up is making antivirals and cancer drugs for Big Pharma—and working to treat reproductive problems on its own ...

Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continued to decline.

Pfizer on Tuesday raised its full-year profit forecast for the second quarter in a row as robust demand for its blockbuster ...

And despite the sales slump in the U.S. this past quarter, Pfizer’s Prevnar dynasty still leads in pediatric pneumococcal vaccination worldwide and among conjugated pneumococcal vaccines for adults in ...

The dramatic bidding war kicked off last week with Novo's surprise play for Metsera, which had already agreed to be acquired ...

Pfizer posts Q3 earnings beat and raises EPS guidance, but weaker COVID product sales weigh on overall revenue momentum.

A fierce US$10 billion bidding war for the Nasdaq-listed anti-obesity drug maker Metsera has resulted in Pfizer emerging with ...

The 11th-hour attempt by Novo to snatch away Metsera, which Pfizer had agreed to buy in September, has upended debate around ...

Metsera, a New York-based biopharmaceutical start-up founded in 2022, is developing next-generation medicines for obesity and ...

Dow Jones Top Company Headlines at 1 PM ET: Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup | Pfizer ... Pfizer, Novo Nordisk Escalate Bidding War for Weight-Loss Drug Startup ...

In the complaint against Patrick James, the bankrupt auto supplier claims $500,000 was spent on a private chef, $150,000 went toward a personal trainer and $3 million was used to rent a New York ...

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced that 48-week data from its two ongoing Phase II studies of AHB ...